Urothelial cancer of the bladder is a smoking-related cancer and the fifth most common
cancer in the United States. At presentation, up to 25% of patients will have muscle-invasive …

Background Combinations of immune checkpoint inhibitors (ICI) with platinum-based
chemotherapy (PlatinumCT) or with another ICI in the first-line setting for patients with …

Simple Summary Urothelial carcinoma is a malignancy that originates in the genitourinary
tract. It is a heterogeneous disease that can present at different stages, and the treatment …

Immune checkpoint inhibitors (ICIs) are active in metastatic urothelial carcinoma (MUC).
They have joined chemotherapy (CT) as a standard of care. Here, we investigate the activity …

Targeted Therapy in Advanced Bladder Cancer - Urologic Clinics Skip to Main Content
Urologic Clinics Log in Register Log in Subscribe Claim Cart (1 item)1 Skip menu theclinics.com …

Conclusion The development of novel therapies targeting the immune and molecular
pathways of advanced urothelial carcinoma is promising for the improvement of outcomes in …

Background Immune checkpoint inhibitors (ICIs) are used widely for treating metastatic
urothelial carcinoma (mUC). In practical settings, evidence is lacking on the efficacy of ICIs …

Aging is related to cancer, and an increasing incidence of malignant tumors among the older
population is observed [1]. Urinary tumors, such as prostate cancer, bladder cancer (BC) …

Purpose: Five programmed cell death protein 1 or its ligand (L1) inhibitors are approved for
treatment of platinum refractory, locally advanced/unresectable or metastatic urothelial …

The mechanisms underlying the resistance to immune checkpoint inhibitors (ICIs) therapy in
metastatic urothelial carcinoma (mUC) patients are not clear. It is of great significance to …